Fasenra Dosage/Direction for Use

Fasenra treatment should be initiated by physicians experienced in the diagnosis and treatment of severe asthma.
After proper training in the subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions (see Precautions), patients with no known history of anaphylaxis or their caregivers may administer Fasenra if their physician determines that it is appropriate, with medical follow-up as necessary. Self-administration should only be considered in patients already experienced with Fasenra treatment.
Posology: The recommended dose of benralizumab is 30 mg by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter. If an injection is missed on the planned date, dosing should resume as soon as possible on the indicated regimen; a double dose must not be administered.
Fasenra is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.
Elderly: No dose adjustment is required for elderly patients (see Pharmacology: Pharmacokinetics under Actions).
Renal and hepatic impairment: No dose adjustment is required for patients with renal or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Fasenra in children aged 6 to 18 years have not been established.
No data are available for children aged 6 to 11 years old. Currently available data in children 12 to less than 18 years old are described in Adverse Reactions and Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions but no recommendation on a posology can be made.
Method of administration: Fasenra is administered as a subcutaneous injection.
It should be injected into the thigh or abdomen. If the healthcare professional or caregiver administers the injection, the upper arm can also be used. It should not be injected into areas where the skin is tender, bruised, erythematous, or hardened.
Comprehensive instructions for administration using the pre-filled pen (Fasenra Pen) are provided in the 'Instructions for Use'.